Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Disease Category: Depression (Major/Severe)
Location: United States, IL
A phase 3, randomized, double blind, parallel group, placebo-controlled, fixed dose study comparing the efficacy and safety of 2 doses (10 and 15mg) of Lu AA21004 in acute treatment of adults with major depressive disorder.
The purpose of this study is to evaluate if 10 and 15mg of Lu AA21004 (the study drug) once a day compared with placebo will improve major depressive symptoms after eight weeks of treatment in patients with major depressive disorder.
Please contact Alexian Brothers for more information on participation.
CW ID: 176876
Date Last Changed:
July 22, 2013
Alexian Brothers Hospital Network1786 Moon Lake Boulevard, Suite 200Hoffman Estates, IL 60169Phone: 847-230-3599
Alexian Brothers Hospital Network
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.